Scinai Immunotherapeutics Reports Strong First-Half 2026 Results and Advances U.S. Clinical Manufacturing Program

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has reported its financial results for the first half of 2026, highlighting a period of strategic advancement and revenue growth. The company, which combines therapeutic development with a revenue-generating contract development and manufacturing organization (CDMO), saw first-half revenue increase to $949,000, up from $773,000 in the prior-year period. This growth is attributed to the expansion of its CDMO services and the commencement of new projects.

Notably, Scinai's committed customer orders reached approximately $3.1 million as of Aug. 16, 2026, including approximately $2.1 million already invoiced. This robust order book underscores the company's ability to attract and retain clients in the competitive biopharmaceutical manufacturing sector. The company is also advancing an expanded clinical manufacturing and chemistry, manufacturing and controls (CMC) program for a U.S.-based biopharmaceutical company. This program, which has already received approximately $650,000 in cash payments and advances, is intended to support an investigational drug product toward a U.S. investigational new drug (IND) submission and Phase III clinical development. While a definitive agreement is still under negotiation, the substantive activities underway indicate strong client commitment and trust in Scinai's capabilities.

Financially, Scinai reported an operating loss of approximately $4.6 million for the first half, compared with $3.8 million in the same period last year. However, the company achieved net income of approximately $1.6 million, a significant improvement from a net loss of approximately $4.1 million in the prior-year period. This turnaround was primarily driven by a $6.4 million bargain purchase gain associated with the acquisition of Recipharm Israel, which has bolstered the company's asset base and operational capacity.

As of June 30, 2026, Scinai held approximately $2.9 million in cash, cash equivalents, and restricted cash. This liquidity position provides the company with the necessary runway to continue its operations and advance its therapeutic programs. The company continues to make progress on its PC111 and NanoAbs therapeutic programs, which are central to its long-term growth strategy.

Investors and stakeholders will have the opportunity to gain deeper insights into Scinai's recent developments and future prospects during an investor webinar scheduled for Aug. 26, 2026. The webinar will cover recent developments, financial performance, and upcoming milestones, offering a comprehensive view of the company's trajectory.

For more details on the full press release, interested parties can visit https://nnw.fm/Be7Ky. Additionally, the latest news and updates relating to Scinai are available in the company's newsroom at https://nnw.fm/SCNI.

Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. Its pipeline includes therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. The company also owns Scinai Biopharma Services Ltd., a CDMO providing development and manufacturing services through facilities in Jerusalem and Yavne, Israel.